These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 18258120)

  • 1. Cost-effectiveness of antiviral stockpiling and near-patient testing for potential influenza pandemic.
    Siddiqui MR; Edmunds WJ
    Emerg Infect Dis; 2008 Feb; 14(2):267-74. PubMed ID: 18258120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investment decisions in influenza pandemic contingency planning: cost-effectiveness of stockpiling antiviral drugs.
    Lugnér AK; Postma MJ
    Eur J Public Health; 2009 Oct; 19(5):516-20. PubMed ID: 19692550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and cost-effectiveness of expanded antiviral prophylaxis and adjuvanted vaccination strategies for an influenza A (H5N1) pandemic.
    Khazeni N; Hutton DW; Garber AM; Owens DK
    Ann Intern Med; 2009 Dec; 151(12):840-53. PubMed ID: 20008760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of influenza in adults older than 65 years of age: cost-effectiveness of rapid testing and antiviral therapy.
    Rothberg MB; Bellantonio S; Rose DN
    Ann Intern Med; 2003 Sep; 139(5 Pt 1):321-9. PubMed ID: 12965940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of pharmaceutical-based pandemic influenza mitigation strategies.
    Newall AT; Wood JG; Oudin N; MacIntyre CR
    Emerg Infect Dis; 2010 Feb; 16(2):224-30. PubMed ID: 20113551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination versus treatment of influenza in working adults: a cost-effectiveness analysis.
    Rothberg MB; Rose DN
    Am J Med; 2005 Jan; 118(1):68-77. PubMed ID: 15639212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B.
    Turner D; Wailoo A; Nicholson K; Cooper N; Sutton A; Abrams K
    Health Technol Assess; 2003; 7(35):iii-iv, xi-xiii, 1-170. PubMed ID: 14609480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of combination antiviral therapy in pandemic influenza and stockpiling implications.
    Tsiodras S; Mooney JD; Hatzakis A
    BMJ; 2007 Feb; 334(7588):293-4. PubMed ID: 17289732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preparing for pandemic influenza: should hospitals stockpile oseltamivir?
    Cinti S; Chenoweth C; Monto AS
    Infect Control Hosp Epidemiol; 2005 Nov; 26(11):852-4. PubMed ID: 16320980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitigation of pandemic influenza: review of cost-effectiveness studies.
    Lugnér AK; Postma MJ
    Expert Rev Pharmacoecon Outcomes Res; 2009 Dec; 9(6):547-58. PubMed ID: 19941432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economics of neuraminidase inhibitor stock piling for pandemic influenza, Singapore.
    Lee VJ; Phua KH; Chenm MI; Chow A; Ma S; Goh KT; Leo YS
    Emerg Infect Dis; 2006 Jan; 12(1):95-102. PubMed ID: 16494724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of influenza symptoms in healthy adults.
    Rothberg MB; He S; Rose DN
    J Gen Intern Med; 2003 Oct; 18(10):808-15. PubMed ID: 14521643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economics of stockpiling for an influenza pandemic.
    Dhankhar P; Dasbach EJ; Elbasha EH
    Lancet Infect Dis; 2009 Aug; 9(8):459-60. PubMed ID: 19628168
    [No Abstract]   [Full Text] [Related]  

  • 14. Post-exposure influenza prophylaxis with oseltamivir: cost effectiveness and cost utility in families in the UK.
    Sander B; Hayden FG; Gyldmark M; Garrison LP
    Pharmacoeconomics; 2006; 24(4):373-86. PubMed ID: 16605283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeling the worldwide spread of pandemic influenza: baseline case and containment interventions.
    Colizza V; Barrat A; Barthelemy M; Valleron AJ; Vespignani A
    PLoS Med; 2007 Jan; 4(1):e13. PubMed ID: 17253899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic analysis of pandemic influenza vaccination strategies in Singapore.
    Lee VJ; Tok MY; Chow VT; Phua KH; Ooi EE; Tambyah PA; Chen MI
    PLoS One; 2009 Sep; 4(9):e7108. PubMed ID: 19771173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiviral agents for influenza: a comparison of cost-effectiveness data.
    Lynd LD; Goeree R; O'Brien BJ
    Pharmacoeconomics; 2005; 23(11):1083-106. PubMed ID: 16277546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic versus static models in cost-effectiveness analyses of anti-viral drug therapy to mitigate an influenza pandemic.
    Lugnér AK; Mylius SD; Wallinga J
    Health Econ; 2010 May; 19(5):518-31. PubMed ID: 19382106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic model for emergency use authorization of intravenous peramivir.
    Lee BY; Tai JH; Bailey RR; McGlone SM; Wiringa AE; Zimmer SM; Smith KJ; Zimmerman RK
    Am J Manag Care; 2011 Jan; 17(1):e1-9. PubMed ID: 21485418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and cost-effectiveness of vaccination against pandemic influenza (H1N1) 2009.
    Khazeni N; Hutton DW; Garber AM; Hupert N; Owens DK
    Ann Intern Med; 2009 Dec; 151(12):829-39. PubMed ID: 20008759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.